Jonathan R Brody

List of Publications by Year
in descending order

Version: 2024-02-01

66 papers	3,141 citations	201674 27 h-index	161849 54 g-index
67 all docs	67 docs citations	67 times ranked	5735 citing authors

#	Article	IF	Citations
1	Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discovery, 2018, 8, 1112-1129.	9.4	676
2	Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1106-15.	7.1	376
3	Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle, 2009, 8, 1930-1934.	2.6	152
4	Structural Implications for Selective Targeting of PARPs. Frontiers in Oncology, 2013, 3, 301.	2.8	121
5	Understanding and targeting the diseaseâ€related RNA binding protein human antigen R (HuR). Wiley Interdisciplinary Reviews RNA, 2020, 11, e1581.	6.4	119
6	Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Gastroenterology, 2016, 150, 48-63.	1.3	90
7	Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells. Cancer Research, 2017, 77, 4460-4471.	0.9	87
8	Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis. Oncotarget, 2016, 7, 74043-74058.	1.8	86
9	HuR Status is a Powerful Marker for Prognosis and Response to Gemcitabine-Based Chemotherapy for Resected Pancreatic Ductal Adenocarcinoma Patients. Annals of Surgery, 2010, 252, 499-506.	4.2	84
10	Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma. Modern Pathology, 2009, 22, 651-659.	5.5	83
11	Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer Biology and Therapy, 2008, 7, 1496-1506.	3.4	82
12	Delivery of Therapeutics Targeting the mRNA-Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor Growth. Cancer Research, 2016, 76, 1549-1559.	0.9	74
13	Metabolic Dependencies in Pancreatic Cancer. Frontiers in Oncology, 2018, 8, 617.	2.8	60
14	Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors. Cancer Research, 2017, 77, 5011-5025.	0.9	59
15	ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications. Molecular Cancer Therapeutics, 2019, 18, 1899-1908.	4.1	52
16	STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair. Clinical Cancer Research, 2018, 24, 1917-1931.	7.0	48
17	Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers. Clinical Cancer Research, 2019, 25, 724-734.	7.0	48
18	Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells. Oncotarget, 2015, 6, 27312-27331.	1.8	47

#	Article	IF	Citations
19	HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells. Molecular Cancer Research, 2016, 14, 599-611.	3.4	45
20	pp32 (ANP32A) Expression Inhibits Pancreatic Cancer Cell Growth and Induces Gemcitabine Resistance by Disrupting HuR Binding to mRNAs. PLoS ONE, 2010, 5, e15455.	2.5	42
21	The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells. Molecular Cancer Research, 2019, 17, 1815-1827.	3.4	40
22	dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer. Cancer Biology and Therapy, 2014, 15, 688-698.	3.4	39
23	CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype. Molecular Cancer Research, 2017, 15, 696-707.	3.4	39
24	Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition. Molecular Cancer Research, 2019, 17, 2029-2041.	3.4	37
25	WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner. Scientific Reports, 2016, 6, 33323.	3.3	33
26	RNA binding protein HuR regulates extracellular matrix gene expression and pH homeostasis independent of controlling HIF-1Î± signaling in nucleus pulposus cells. Matrix Biology, 2019, 77, 23-40.	3.6	32
27	Complex HuR function in pancreatic cancer cells. Wiley Interdisciplinary Reviews RNA, 2018, 9, e1469.	6.4	29
28	Evaluation of Post-transcriptional Gene Regulation in Pancreatic Cancer Cells: Studying RNA Binding Proteins and Their mRNA Targets. Methods in Molecular Biology, 2019, 1882, 239-252.	0.9	29
29	A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 5092-5101.	7.0	28
30	Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer. Cancer Research, 2019, 79, 4491-4502.	0.9	27
31	Personalized therapy for pancreatic cancer: Do we need better targets, arrows, or both?. Discovery Medicine, 2016, 21, 117-23.	0.5	27
32	Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer. Annals of Surgery, 2018, 267, 364-369.	4.2	26
33	Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment. Oncotarget, 2017, 8, 37923-37934.	1.8	23
34	The Past, Present, and Future of Biomarkers: A Need for Molecular Beacons for the Clinical Management of Pancreatic Cancer. Advances in Surgery, 2011, 45, 301-321.	1.3	22
35	Elevated HuR in Pancreas Promotes a Pancreatitis-Like Inflammatory Microenvironment That Facilitates Tumor Development. Molecular and Cellular Biology, 2018, 38, .	2.3	22
36	Gemcitabine-loaded microbubble system for ultrasound imaging and therapy. Acta Biomaterialia, 2021, 130, 385-394.	8.3	21

#	Article	IF	Citations
37	Reduction of pp32 expression in poorly differentiated pancreatic ductal adenocarcinomas and intraductal papillary mucinous neoplasms with moderate dysplasia. Modern Pathology, 2007, 20, 1238-1244.	5.5	19
38	Novel Targets in Pancreatic Cancer Research. Seminars in Oncology, 2015, 42, 177-187.	2.2	19
39	The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria. Molecular Cancer Therapeutics, 2021, 20, 2166-2176.	4.1	19
40	Envisioning the future of precision oncology trials. Nature Cancer, 2021, 2, 9-11.	13.2	19
41	MUC1 Promoterâ€“Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer. Molecular Cancer Research, 2015, 13, 439-448.	3.4	18
42	Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer. Cancer Biology and Therapy, 2018, 19, 249-253.	3.4	18
43	RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer. Molecular Cancer Research, 2019, 17, 508-520.	3.4	17
44	HuR's role in gemcitabine efficacy: an exception or opportunity?. Wiley Interdisciplinary Reviews RNA, 2011, 2, 435-444.	6.4	15
45	Psychosocial distress is dynamic across the spectrum of cancer care and requires longitudinal screening for patient-centered care. Supportive Care in Cancer, 2022, 30, 4255-4264.	2.2	9
46	Alterations of type II classical cadherin, cadherinâ€10 (CDH10), is associated with pancreatic ductal adenocarcinomas. Genes Chromosomes and Cancer, 2017, 56, 427-435.	2.8	8
47	Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties. Molecular Cancer Therapeutics, 2021, 20, 553-563.	4.1	7
48	Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy. Oncotarget, 2016, 7, 21812-21824.	1.8	7
49	Effect of Hypercapnia, an Element of Obstructive Respiratory Disorder, on Pancreatic Cancer Chemoresistance and Progression. Journal of the American College of Surgeons, 2020, 230, 659-667.	0.5	6
50	Combined Targeting of PARG and Wee1 Causes Decreased Cell Survival and DNA Damage in an S-Phaseâ€“Dependent Manner. Molecular Cancer Research, 2021, 19, 207-214.	3.4	6
51	The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma. Molecular and Cellular Biology, 2022, 42, .	2.3	6
52	PARP Inhibitors for Chemopreventionâ€”Letter. Cancer Prevention Research, 2014, 7, 1170-1171.	1.5	5
53	A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. Journal of the American College of Surgeons, 2018, 226, 596-603.	0.5	5
54	AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with PARG Inhibition. Molecular Cancer Research, 2021, 19, 565-572.	3.4	5

#	Article	IF	Citations
55	Disparities in Electronic Screening for Cancer-Related Psychosocial Distress May Promote Systemic Barriers to Quality Oncologic Care. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 765-773.e4.	4.9	5
56	Genetic Drivers of Pancreatic Cancer Are Identical Between the Primary Tumor and a Secondary Lesion in a Long-Term (>5 Years) Survivor After a Whipple Procedure. Journal of Pancreatic Cancer, 2018, 4, 81-87.	0.9	4
57	A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience. Surgical Oncology, 2020, 33, 118-125.	1.6	4
58	HuR Plays a Role in Double-Strand Break Repair in Pancreatic Cancer Cells and Regulates Functional BRCA1-Associated-Ring-Domain-1(BARD1) Isoforms. Cancers, 2022, 14, 1848.	3.7	4
59	Targeting homologous recombination addicted tumors: challenges and opportunities. Annals of Pancreatic Cancer, 2020, 3, 6-6.	1.2	3
60	A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Journal of Pancreatic Cancer, 2019, 5, 12-21.	0.9	2
61	Disparities in pancreatic cancer care and research in Native Americans: Righting a history of wrongs. Cancer, 2022, 128, 1560-1567.	4.1	2
62	CXCR4 signaling identifies a role for IFT2 in ER-negative breast cancers. Cancer Biology and Therapy, 2010, 10, 615-616.	3.4	1
63	Ultra-fast conductive media for RNA electrophoretic mobility shift assays. BioTechniques, 2020, 68, 101-105.	1.8	1
64	Rules for scientific progress while living with the COVID-19 Pandemic: from â€˜benchsideâ€™ to â€˜fireside.â€™. Cancer Biology and Therapy, 2020, 21, 581-582.	3.4	1
65	Fusing Transcriptomics to Progressive Prostate Cancer. American Journal of Pathology, 2014, 184, 2608-2610.	3.8	0
66	Precious Data: Interim Report from the Jefferson Pancreas Tumor Registry. Journal of Pancreatic Cancer, 2018, 4, 17-24.	0.9	0